Glial fibrillary acidic protein (GFAP) is an astrocyte structural
protein. GFAP has been authorized as one of the biomarkers for mild
traumatic brain injury (mTBI) and its level shows a correlation with the
clinical severity after the injury.
Read more and
GFAP is a member of the type III intermediate filament that provides
support and strength to cells and sustains the cell shape. In 2018,
GFAP, together with Ubiquitin C-terminal hydrolase-L1 (UCH-L1), received
approval as a biomarker for concussion in adults by the U.S. Food and
Drug Administration (FDA). This represented a great milestone in the
blood biomarker development for neurological disorders. Furthermore, it
can be detected in serum already within the first few hours after a head
HyTest offers several well-characterized monoclonal antibodies that are specific to GFAP and which may be used for the quantification of GFAP in serum, plasma, or CSF.
Cat# 4G25:Glial Fibrillary Acidic Protein, Antibody